2015
Fenger, J. 2015. Investigating the Biological and Molecular Consequences of MiR-9 Dysregulation in Canine Mast Cell Tumors and Osteosarcoma. PhD Dissertation, Ohio State University. (CnOb)
2013
Couto, J. 2013. Biologic Activity of the Novel Small Molecule STAT3 Inhibitor Against Canine Osteosarcoma Cell Lines. The Ohio State University, M.Sc. dissertation.
Davis, L.E., N.E. Hofmann, G. Li, E.T. Huang, M.M. Loriaux, S. Bracha, S.C. Helfand, J.E. Mata, K. Marley, and A. Mansoor. 2013. A case study of personalized therapy for osteosarcoma. Pediatric blood & cancer. 60:1313-1319.
Milovancev, M., I. Hilgart-Martiszus, M.J. McNamara, C.P. Goodall, B. Seguin, S. Bracha, and S.I. Wickramasekara. 2013. Comparative analysis of the surface exposed proteome of two canine osteosarcoma cell lines and normal canine osteoblasts. BMC veterinary research. 9:116.
Piskun, C.M., and T.J. Stein. 2013. β-Catenin transcriptional activity is minimal in canine osteosarcoma and its targeted inhibition results in minimal changes to cell line behaviour. Vet. & Comp. Oncology: doi: 10.1111/vco.12077.
2012
Book, A.P. 2012. Investigating procaspase-3 as a potential therapeutic target in canine osteosarcoma. Master of Science Thesis. University of Illinois.
Couto, J.I., M.D. Bear, J. Lin, M. Pennel, S.K. Kulp, W.C. Kisseberth, and C.A. London. 2012. Biologic activity of the novel small molecule STAT3 inhibitor LLL12 against canine osteosarcoma cell lines. BMC veterinary research. 8:244.
2011
Fossey, S., M. Bear, W. Kisseberth, M. Pennell, and C. London. 2011. Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines. BMC cancer. 11:125.
McCleese, J. 2011. Investigating the Biological and Biochemical Consequences of Met Function and Dysfunction in Canine Osteosarcoma. PhD Dissertation, The Ohio State University.
2010
Fossey, S. 2010. Characterization of STAT3 Activation in Osteosarcoma. PhD Dissertation, Ohio State University.
2009
Fossey, S.L., A.T. Liao, J.K. McCleese, M.D. Bear, J. Lin, P.-K. Li, W.C. Kisseberth, and C.A. London. 2009. Characterization of STAT3 activation and expression in canine and human osteosarcoma. BMC cancer. 9:81.
McCleese, J.K., M.D. Bear, S.L. Fossey, R.M. Mihalek, K.P. Foley, W. Ying, J. Barsoum, and C.A. London. 2009. The novel HSP90 inhibitor STA‐1474 exhibits biologic activity against osteosarcoma cell lines. Int. J.Cancer. 125:2792-2801.
